Skip to main content

Table 1 Patient and tumor characteristics

From: Tamoxifen-predictive value of gene expression signatures in premenopausal breast cancer: data from the randomized SBII:2 trial

Characteristics

Patients with gene signatures (n = 437)

Patients without gene signatures (n = 123)

Control group n (%)

Tam-treated group n (%)

Control group n (%)

Tam-treated group n (%)

Age (years)

 Median

45

45

45

47

 Range

27–54

26–57

29–58

31–55

Tumor size (mm)

 ≤ 20

86 (39)

69 (32)

35 (55)

17 (29)

 > 20

134 (61)

148 (68)

29 (45)

41 (71)

 Missing

0

0

0

1

Nodal status

 Node-negative

57 (26)

62 (29)

18 (28)

21 (36)

 Node-positive

162 (74)

154 (71)

46 (72)

38 (64)

 N1

105 (48)

108 (50)

34 (53)

28 (48)

 N2

57 (26)

46 (21)

12 (19)

10 (17)

 Missing

1

1

0

0

NHG

 1

24 (11)

22 (11)

1 (15)

5 (11)

 2

88 (42)

87 (43)

27 (52)

18 (38)

 3

99 (47)

93 (46)

17 (33)

24 (51)

 Missing

9

15

12

12

ER

 Positive

154 (70)

139 (66)

37 (64)

32 (63)

 Negative

63 (29)

72 (34)

21 (36)

19 (37)

 Missing

3

6

6

8

PR

 Positive

148 (68)

132 (61)

37 (64)

31 (62)

 Negative

71 (32)

84 (39)

21 (36)

19 (38)

 Missing

1

1

6

9

HER2

 Negative

166 (82)

167 (87)

37 (95)

30 (88)

 Positive

36 (18)

26 (12)

2 (5)

4 (12)

 Missing

18

24

25

25

Ki67 (%)

 Median

34

32

27

28

 Range

2–89

3–88

7–53

9–51

 Missing

16

14

41

43

Histopathological type

 Ductal/NST

177 (86)

167 (82)

32 (74)

33 (85)

 Lobular

16 (8)

18 (9)

6 (14)

3 (8)

 Medullary

10 (5)

10 (5)

4 (9)

1 (3)

 Other

4 (2)

8 (4)

1 (2)

2 (5)

 Missing

13

14

21

20

TILs (%)

 < 10

111 (51)

116 (54)

18 (58)

7 (35)

 10–49

79 (36)

67 (31)

7 (23)

8 (40)

 50–100

28 (13)

34 (16)

6 (19)

5 (25)

Missing

2

0

33

39

PAM50 subtype

 Luminal A

101 (46)

90 (42)

–

–

 Luminal B

41 (19)

42 (19)

–

–

 HER2-enriched

39 (18)

35 (16)

–

–

 Basal-like

39 (18)

50 (23)

–

–

 Missing

0

0

59

59

  1. Patient and tumor characteristics for the whole study cohort with (n = 437) and without (n = 123) available gene expression, respectively, stratified by study arm
  2. ER estrogen receptor, HER2 human epidermal growth factor receptor 2, NHG Nottingham histological grade, NST no special type, PR progesterone receptor, TAM tamoxifen, TILs tumor-infiltrating lymphocytes